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Abstract
Background: Multiple sclerosis (MS) is a life-long condition primarily affecting younger adults. Neurogenic bowel
dysfunction (NBD) occurs in 50–80% of these patients and is the term used to describe constipation and faecal
incontinence, which often co-exist. Data from a pilot study suggested feasibility of using abdominal massage for
the relief of constipation, but the effectiveness remains uncertain.
Methods/design: This is a multi-centred patient randomised superiority trial comparing an experimental strategy
of once daily abdominal massage for 6 weeks against a control strategy of no massage in people with MS who
have stated that their constipation is bothersome. The primary outcome is the Neurogenic Bowel Dysfunction Score
at 24 weeks. Both groups will receive optimised advice plus the MS Society booklet on bowel management in MS,
and will continue to receive usual care.
Participants and their clinicians will not be blinded to the allocated intervention. Outcome measures are primarily
self-reported and submitted anonymously. Central trial staff who will manage and analyse the trial data will be
unaware of participant allocations. Analysis will follow intention-to-treat principles.
Discussion: This pragmatic randomised controlled trial will demonstrate if abdominal massage is an effective,
cost-effective and viable addition to the treatment of NBD in people with MS.
Trial registration: ClinicalTrials.gov, ISRCTN85007023. Registered on 10 June 2014.
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Background
Multiple sclerosis (MS) is a life-long condition primarily
affecting younger adults. There is currently no accurate
data on the exact number of people with MS in the UK,
but it is thought to be between 107,000 and 127,000 [1]
and is growing by around 2.4% per year. Bowel problems
occur much more often in people with MS than in the
normal population. Neurogenic bowel dysfunction (NBD)
is the broad term used to describe constipation and faecal
incontinence (FI) secondary to neurological disease or
trauma and is caused by damage to the nerves controlling
colonic function. In addition confounding factors such as
side effects of medication, poor diet and decreased exer-
cise may compound symptoms. Constipation in people
with MS is usually due to slow colonic transit time and
can be exacerbated by pelvic floor dyssynergia and may
lead to the individual becoming housebound and spending
long periods of time trying to empty their bowels, thus
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limiting their ability to work [2]. In severe cases impaction
occurs, which often requires hospital admission. FI may
co-exist or exist independently, and it is often described
as the most devastating event imaginable, leading to so-
cial and emotional issues and devastating psychosocial
consequence [2].
The costs arising from treating bowel and bladder
problems in people with MS totalled £11 M for National
Health Service (NHS) England in 2013/14 [3, 4]. People
with MS are twice as likely to have a non-elective admis-
sion for constipation as members of the general population
with an average admission cost of £1729 [3, 4].
Bowel management often plays a significant part in the
lives of people with MS, but there is little robust evidence
on effective interventions [2]. Initial management of NBD
includes conservative measures such as modification of
diet and fluids, laxatives or constipating medication, rectal
interventions such as digital rectal stimulation and manual
evacuation of stool, suppositories/enemas progressing to
more invasive and expensive interventions such as rectal
irrigation and surgery (e.g. stoma). Current evidence for
the effectiveness of abdominal massage, the focus of this
trial, has been summarised in a Cochrane Review under-
taken by the Chief Investigator [5]. The review found 11
randomised controlled trials (RCTs) with a total of 268
participants. One of these studies was a pilot trial of
people with MS and abdominal massage, which confirmed
feasibility and was used to determine the sample size of
this RCT [6]. Overall the review authors concluded that
although the results were promising, there was a lack of
unequivocal evidence of effectiveness for abdominal
massage, and they recommended further trials be carried
out in specific populations [5]. As to the mechanism of ac-
tion, there was even less information, with only a small
study in a spinal cord injury (SCI) population suggesting
that changes in anorectal physiology parameters could be
detected during abdominal massage and recommending
further exploration [7, 8].
This background research has led us to design a robust
pragmatic trial to determine the effectiveness and cost-
effectiveness of abdominal massage in people with MS
who have bothersome constipation. The protocol follows
the Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) checklist (see Additional file 1).
The corresponding flow chart for the Abdominal Massage
for Bowel Dysfunction Effectiveness Research (AMBER)
trial is shown in Fig. 1, and the schedule of enrolment,
interventions and assessments is provided in Fig. 2.
Hypothesis
It is hypothesized that the effectiveness and cost-
effectiveness of a strategy of abdominal massage with
optimised advice is superior to optimised advice without
abdominal massage in terms of clinical and cost-
effectiveness at 24 weeks.
Objectives
The AMBER trial will determine/undertake the following:
1. Is an optimised bowel care programme with
abdominal massage more effective and cost-effective
compared to an optimised bowel care programme
alone in reducing the symptoms of NBD in people
with MS?
2. To identify and investigate via a process evaluation
the possible mediating factors that have an impact
on the effectiveness of the intervention (including
intervention fidelity), how these mediating factors
influence effectiveness, and whether the factors
differ between the randomised groups.
3. To undertake a formal economic evaluation of the
interventions from an NHS and societal perspective
with a focus on the NHS and the participants.
4. The physiological effect of abdominal massage on
the bowel (substudy at one of the sites).
5. To validate responsiveness of a new NBD quality
of life questionnaire.
Methods/design
Study design
The present study is a multi-centred, RCT set in routine
care settings comparing the effectiveness of an experi-
mental strategy of once daily abdominal massage for
6 weeks against a control strategy of no massage in
people with MS who have stated that their constipation
is bothersome. An integral part of the project will be the
process evaluation which will follow a mixed methods,
longitudinal, case study design [9, 10]. In addition at one
site only, anorectal physiology studies to determine
mechanism will be conducted in consenting patients in
both groups.
Blinding
Due to the nature of the intervention, participants and
the research team delivering the intervention will not be
blinded to the treatment received. Outcome measures
are primarily self-reported and submitted anonymously.
Those involved in the data analyses and statistics will be
blinded to the group allocation.
Participants
Participants will be included on the condition that they
are over 18 years old (both male and female), have a
diagnosis of MS (in a stable phase, i.e. no MS relapse for
3 months), have had no major change in medication for
1 month, have had no abdominal massage for at least
2 months and are bothered by their constipation.
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Exclusion criteria are inability to undertake the massage
themselves or the lack of a carer willing to do it; those
who are unable to understand the study or give informed
consent; or those who have contraindications to massage,
e.g. history of abdominal/pelvic cancer, hiatus, inguinal or
umbilical hernia, rectal prolapse, inflammatory bowel
disease, pregnancy, past history of volvulus, indwelling
urinary catheters, recent abdominal scars, abdominal
wounds or skin disorders that may make abdominal
massage uncomfortable.
Recent sudden and severe changes in bowel habits and
rectal bleeding are not exclusion criteria but will be
flagged and discussed with the local Principal Investigator
before recruiting to the study.
Detailed study plan
Patient recruitment/consent procedure
The research team at each study centre will be responsible
for identifying potential patients. Following identification
a letter of introduction and an ‘Expression of Interest
Form’ will be posted or given to patients in the routine
clinic. A member of the research team will telephone
those patients who express an interest to provide further
information and to assess eligibility.
If eligible and willing to take part, a time for the partici-
pant to attend clinic will be arranged. An appointment
letter will be posted to the participant along with a 7-day
bowel diary. The participant will be asked to complete the
bowel diary during the week prior to this appointment
and will also be asked to bring someone who is willing to
do the massage to this appointment if required.
Allocation of patients
Patients who provide written informed consent will be
randomly allocated to either the optimised bowel care
programme (control group) or the optimised bowel care
programme and massage (intervention group). Random-
isation will utilise a web-based randomisation system at
the Tayside Clinical Trials Unit. Randomisation will be
stratified by site and minimised on level of disability
(walking unaided, walking aided or wheelchair bound).
Data collection for outcome measurements
Data will be collected via participant-completed question-
naires at baseline and at 6 and 24 weeks. A 7-day bowel
diary will be completed prior to baseline, and a bowel
diary (or bowel and massage diary if allocated to interven-
tion) during weeks 1–6 and at 24 weeks. Completed out-
come data are retuned by post. Demographic and medical
history information will be collected at baseline.
Patient resource questionnaires will also be sent to the
participant at home to complete at 12 and 18 weeks.
Fig. 1 AMBER participant pathway
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Anorectal physiology and colonic transit time data will be
collected from one site only where it is routinely con-
ducted as part of the assessment, and these will be re-
peated at week 24. Figure 1 shows the AMBER participant
pathway and data collected at each time point.
Intervention
Both trial arms
Both intervention and control groups will receive a 6-week
intervention consisting of one outpatient consultation
followed by weekly telephone calls to review adherence.
Thus both groups will have the same amount of health
professional contact. Both groups will receive what we
have termed ‘optimised bowel care’. Often, in people with
MS, bowel care is delivered in a haphazard fashion with
little standardisation or guidelines for treatment. Optimised
care (delivered to both groups) will include advice which
will be reinforced by providing the Bowel Care Advice
Leaflet of the MS Society.
The intervention and control groups will differ as
described:
1. Control group (optimised bowel care). During the
outpatient appointment the participants’ existing
routine bowel care will be reviewed and optimised.
For example, dietary and fluid advice will be given
as well as encouragement to be more active and use
a better defaecation position.
2. Intervention group (abdominal massage and
optimised bowel care). In addition to optimised
bowel care as described for the control group, the
intervention researcher, who will have been trained
in the massage, will teach the participant and/or
their carer how to deliver the abdominal massage.
This will include viewing a short study-specific DVD
showing the massage being given to a patient and
self-massage techniques, a study-specific abdominal
massage training booklet as well as a demonstration
of the technique on the participant. During the
training the carer or participant will try the various
strokes and will be able to ask questions. Possible
adaptations to accommodate a participant’s disability
will also be discussed. It is recommended that the
abdominal massage be included as part of the
Fig. 2 Schedule of enrolment, interventions, and assessments for ‘Abdominal massage for neurogenic bowel dysfunction in people with
multiple sclerosis’
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participant’s usual bowel care regimen. Daily
application was recommended in our pilot study in
people with MS, and this was found to be acceptable
with 80% adherence reported in the massage diary [6].
Both groups will have weekly telephone calls (lasting
approximately 10 minutes; weeks 1–6) where they will
discuss any changes/difficulties with bowel management.
The intervention group participants will also discuss
frequency of use and any problems in using abdominal
massage.
Participants randomised to the control group will be
given access to the training materials for the massage at
the end of their follow-up visit (24 weeks). Each trial
centre will decide if they will hold practical training ses-
sions for their control participants and will make them
aware of this at the baseline visit.
Abdominal massage technique
The ideal position of the participant is supine, with ap-
propriate head and knee support, in a relaxed atmos-
phere. Adaptations to this position may be required
depending on the patient’s disability. The training videos
provide demonstrations for both supine and sitting and
self- and carer-led massage.
There are four basic strokes with the massage lasting
about 10 minutes.
1. Stroking commences from the small of the back and
follows the dermatome of the vagus nerve, over the
iliac crests and down both sides of the pelvis towards
the groin.
2. Effleurage follows the direction of the ascending
colon across the transverse colon and down the
descending colon. This is also repeated several
times with increasing pressure.
3. Palmar kneading tracks down the descending colon,
up the ascending colon and down the descending
colon once again. Effleurage is repeated and continued
with a relaxing transverse stroke over the abdomen.
4. Vibration over the abdominal wall to relieve flatus
concludes the massage session.
Outcomes
Primary outcome measure
The primary outcome is the difference between the
intervention and the control group in the change in the
Neurogenic Bowel Dysfunction Score (NBDS) [10] at
24 weeks. The NBDS is a 10-item questionnaire covering
frequency of bowel movements, headache, perspiration or
discomfort during defaecation; medication for constipa-
tion or faecal incontinence; time spent on defaecation;
frequency of digital stimulation or evacuation; frequency
of faecal incontinence; flatus; and perianal skin problems.
The maximum score is 47; a score over 14 is considered
severe [11].
Secondary outcome measures
Bowel outcomes are assessed with the following
measures:
 Constipation symptoms. The Constipation Scoring
System (CSS) [12] is used. It measures constipation
symptoms via an 8-item questionnaire with items on
frequency of bowel movement, difficulty with
evacuation, feeling of incomplete evacuation, pain,
length of time for evacuation, assistance with
evacuation, number of failed attempts and the
duration of constipation. Maximum score is 30,
with higher scores indicating greater severity.
 Bowel symptoms. A 7-day bowel diary is used to
record the frequency of bowel movement, time
spent defaecating, stool type (Bristol stool chart)
[13], laxative use, additional interventions, e.g. digital
stimulation, changes in medication and contact with
NHS staff. The diary will be completed for 7 days
on three occasions: prior to trial entry, during
weeks 1–6 and at week 23.
Adherence to massage schedule
A massage diary will be used. The massage intervention
will be recorded in the diary during the intervention
period (1–6 weeks) for the intervention group and will
be used as part of compliance monitoring.
Urinary outcomes
Bladder function will be measured using the Qualiveen
Questionnaire Short Form [14], which consists of an 8-
item questionnaire assessing bladder dysfunction, such as
leakage and signs of incomplete voiding. Often if patients
with MS are suffering from constipation, they report that
their bladder symptoms are worse, especially urgency and
frequency, which can lead to an increase in urinary
incontinence. By using such an outcome measure the
effect of the change in bowel function on the bladder can
be assessed.
Quality of life outcomes
The following quality of life assessments will be used:
 For health status the EuroQol five-dimension
questionnaire (EQ-5DL) [15] generic instrument
will be used. Trial participants will complete the
EQ-5DL at baseline, at 6 weeks and at 24 weeks
post randomisation. This instrument will provide
quality of life weights to compute quality-adjusted
life years (QALYs).
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 The Neurogenic Bowel Impact Score (NBIS, a
patient-reported symptom and quality of life
questionnaire for NBD) will also be used. One
investigator (MC) is developing a patient-reported
symptom and quality of life questionnaire for NBD
as part of a National Institute for Health Research
(NIHR)-funded postdoctoral fellowship. This
questionnaire will be completed at all time points
to allow assessment of the measure’s sensitivity to
change. The development of such a questionnaire
is important for research and clinical practice in
this area.
Economic outcomes
The cost and use of NHS services will be collected via a
‘Patient resource questionnaire’. The cost to the patients
and their families/carers will also be collected via the
Patient resource questionnaire). From this information
we will calculate the incremental costs, QALYs and incre-
mental cost per QALY.
Radio-opaque marker transit tests and anorectal
physiology tests
Standard anorectal physiology tests and colonic transit
studies are routinely undertaken before treatment at one
site (which will recruit 30 MS participants), and the out-
comes will be recorded, as they may have some predict-
ive value. These participants will have a repeat transit
study test at 24 weeks. Transit studies have been used in
previous trials and have been shown to be sensitive to
change [16]. Radio-opaque marker transit studies most
commonly involve the ingestion of a number of Sitzmarks
capsules, each containing different shaped radio-opaque
markers, followed by a single plain abdominal X-ray 5 days
later. These transit studies enable an assessment of total
colonic transit time, but not segmental transit [17, 18].
The radio-opaque markers will be posted to the partici-
pant, who will ingest them and then attend for abdominal
X-ray 5 days later. Out-of-pocket expenses will be paid to
the participant for attending the follow-up transit study.
This is an internal pilot study of the feasibility of under-
taking such tests within this population and their compli-
ance with attending for the repeat tests.
Process evaluation
Meso-level and micro-level contextual data on the inter-
vention sites will be gathered in order to explore pre-
existing background contexts and any changes (e.g. in
local capacity) that might have an impact on delivery or
take-up of the intervention. These data will be gathered
primarily by undertaking interviews with relevant parties
as detailed in Table 1.
Statistical methods
Sample size calculation
The only published data available on the NBDS to inform
sample size calculations is from our own pilot trial in the
MS population [6]. Based on these data a sample size of
60 per group was calculated as necessary to detect a differ-
ence between groups of 4.21 (standard deviation, SD 7.02)
at a 5% level of significance with 90% power. Thus for a
fully powered study the sample size, allowing for a 20%
drop-out, is 150. However, it was suggested by the funder
that this figure be reviewed and increased. Therefore we
have increased our sample size to 200 (100 per group),
which would allow for greater than expected attrition.
Statistical analyses
Analysis will be performed for the intention-to-treat popu-
lation and reported in accordance with the Consolidated
Standards of Reporting Trials (CONSORT) statement [19,
20] and the International Conference on Harmonisation
(ICH) E9 ‘Statistical Principles in Clinical Trials’ [21]. All
trial data will be summarized by treatment group and total.
Continuous data will be reported as mean (SD), categorical
data as N (%). Primary outcome analysis will be a general
linear model comparing the difference in mean NBDS
score at 24 weeks between the intervention and control
groups with adjustment for the minimisation covariates
and baseline score. Other covariates will be considered for
further adjustment and if necessary stated in the statistical
analysis plan prior to data lock. Secondary analysis will
use similar analysis of covariance (ANCOVA) models, cor-
recting for baseline characteristics. A two-sided p value of
0.05 will be taken as significant for each outcome.
The extent of missing data will be explored in the
outcomes, especially the primary outcome. Patterns of
missing data will be explored and predictors of missing-
ness examined, especially if these vary by intervention. If
necessary, multiple imputations will be utilised to impute
missing data assuming the missingness mechanism is
missing at random (MAR). A detailed statistical analysis
plan will be agreed to before the end of data entry and
before the treatment code is broken.
Table 1 Process evaluation data collection
Details
Documentary analysis related to health care trusts; local capacity/
budgets at 10 implementation sites
Semi-structured interviews (n = 85)
• 20 patients in intervention arm (interviewed twice)
• 2 staff members from each site (n = 10 sites), interviewed twice
• 5 stakeholder interviews
Bowel diary analysis (5 patients)
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Subgroup analysis
Subgroup analyses will be carried out by first testing for a
subgroup factor by trial group interaction. If this is signifi-
cant at the 5% level, results will be estimated separately by
the different subgroups. These analyses will also be re-
peated for all the secondary outcomes. This will include a
secondary analysis comparing those who undertook the
massage themselves to those receiving carer-delivered mas-
sage. Appropriate transformations of outcomes will be per-
formed where necessary to satisfy modelling assumptions.
Process evaluation analysis
Interviews will be coded and analysed using techniques
of framework analysis [22], assisted by QSR NVivo 10.
The analysis will pay particular attention to barriers and
facilitators to uptake of abdominal massage for MS pa-
tients, synthesising staff and patient views into an overall
implementation narrative. Staff interviews will be ana-
lysed longitudinally, using a framework matrix to explore
developments over the two time periods.
Progress tracking data for trial recruitment and adher-
ence will be synthesised in narrative form with themes
from the qualitative data; thus the mixed methods will
complement each other rather than be used to triangu-
late and verify either data source. The process evaluation
will also draw on the results of the participant massage
diaries, seeking to explain adherence/intensity rates via
qualitative interview data. Informed by the realist evalu-
ation approach, the analysis will seek to identify key mech-
anisms involved in the implementation of the intervention,
barriers and facilitators to success and what might impinge
on outcomes. Finally, the lessons learned from the process
evaluation will provide analytical input into the optimisa-
tion of the intervention for future implementation into
practice if effectiveness is demonstrated.
Economic analysis
The cost of abdominal massage and optimal bowel care
relative to optimised bowel care alone in people with
MS who have NBD will be considered from NHS and
societal perspectives. Health care resource use by pa-
tients in both trial arms will be collected at each of the
follow-up time periods (i.e. weeks 1–6, 12, 18 and 24).
This will include contact with health professionals and
medications prescribed. These will be costed using NHS
pay and prices or, where appropriate, using other (e.g.
market-based) sources. Health-related quality of life will
be assessed using the EQ-5DL questionnaire completed
by all patients at baseline, at 6 weeks and at 24 week
follow-up. QALYs associated with each arm of the trial
will be calculated using the UK tariff scores (utility
values) from the EQ-5DL descriptive system [23, 24].
Data on intervention costs and patient resource use
will be aggregated and the statistical significance of
differences in cost per patient between trial arms assessed
by appropriate methods depending on the distributional
characteristics of the data. Depending on the outcome
measure, which would be QALYs, NBDS or both, if there
is no statistically significant evidence that one treatment
strategy is more effective than another, a cost-minimisation
framework will be used, and the less expensive form of
care will be recommended. If one strategy appears to
be dominant (i.e. to be more effective and less costly
than the alternative), the uptake will be recommended.
If one form of care appears to be more effective and
more expensive than the comparator, estimates of in-
cremental cost-effectiveness (and cost-utility) ratios will
be generated.
Adverse events
The AMBER trial involves treatments which are well
established in clinical practice for individuals with MS
who have bothersome constipation; therefore adverse
events (AEs) (although these are unlikely) will be those
observed in everyday practice associated with optimised
bowel care and abdominal massage. Expected AEs arising
from the treatments are noted below and thus will not be
collected as AEs but noted in the weekly follow-up data
collection.
 Increased flatulence
 Abdominal cramps
 Stomach rumblings/noises
 Loose stool, which in some instances may lead to
faecal incontinence.
All AEs and serious AEs will be assessed for serious-
ness, causality, severity and expectedness and will be
reported to the relevant regulatory bodies.
End of study/discontinuation
The trial may be prematurely discontinued on the basis
of new safety information or for other reasons given by
the Data Monitoring and Ethics Committee (DMEC)
and/or Trial Steering Committee (TSC), Sponsor, regula-
tory authority or ethics committee concerned. The end of
the study is the last participant’s final 24 week follow-up.
Data and confidentiality
All trial participants are given an individual trial number
which will be used on all Case Report Forms for that
participant. All collected information will be kept strictly
confidential and will be stored in accordance with the
UK Data Protection Act 1998 and retained in accordance
with the latest Directive on Good Clinical Practice (GCP)
and local policy. Data will be entered into the secure trial
database by the data coordinator based at the AMBER
central office at Glasgow Caledonian University.
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Discussion
This study is a pragmatic patient-oriented trial aiming to
capture a true representation of the actual patient popu-
lation of interest. We know from previous work and
from reviews that there is a lack of evidence-based inter-
ventions for NBD accompanied by a lack of willingness
in patients and indeed clinicians to discuss such intimate
problems. As discussed earlier the cost to the NHS and
to the patient is considerable and increasing; moreover
the effect on quality of life both for patients and carers
is significant and disabling. The lack of robust evidence
on effective management leads to inconsistent advice
and confused management pathways. MS is a long-term
condition, and supported self-management is important.
Abdominal massage as an adjunct to treatment offers a
safe, non-invasive and non-drug intervention which
could be undertaken by the patient or a carer. As such it
is likely to be an attractive option for many.
Should the trial demonstrate that abdominal massage is
effective we will have the necessary information from our
process evaluation to identify the barriers and enablers to
implementation of such a self-management technique.
Easy integration into standard local pathways should be
possible, as the training required for clinicians and
patients (or carers) is minimal. The process evaluation will
also identify if this training has been adequate.
Trial status
The AMBER trial is currently recruiting in 12 UK centres
and is recruiting to target. The first patient was randomised
on 22 January 2015, and recruitment is due to end June
2016 and follow-up completed by the end of December
2016. The trial has both a TSC and a DMEC, and both
oversight groups have convened twice. The DMEC
reviewed their report in December 2015 and had no issues
with the trial. They commended the trial team on recruiting
to target. For the trial protocol and updates see Clinical-
Trials.gov and the trial website http://www.gcu.ac.uk/
amber/. The trial registration number is ISRCTN85007023.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 124 kb)
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